BACKGROUND
Although CML has led to a life expectancy of patients with CML-CP closer to that of the general population, measures and interventions are challenging to manage due to the great heterogeneity of patients.1-14 Data on patient experiences and/or treatment switching, improve QOL, and often necessitate a treatment change. The decreasing proportion of physicians who reported some treatment goals as their patients’ progress to later lines of therapy highlights the challenge of managing patients with advanced disease

METHODS
CML-CP was conducted among patients with CML-CP and treating physicians. Results of the qualitative interviews of 21 patients and 31 physicians (published previously) were used to inform topics for the online quantitative surveys.15 Patients previously interviewed for treatment decisions for patients with CML. Physicians spent ≥50% of their time caring for patients, treated ≥10 patients with CML-CP (>30% receiving ≥10 treatments in ≥3L or ≥4L). Physicians must have been transplant specialists or hematologists/stem cell doctors in practice for ≥3 years and have generally prepared for treatment decisions for patients with CML. Physicians spent ≥50% of their time caring for patients (≥10 patients with CML-CP). Physicians spent ≥50% of their time caring for patients with CML-CP ≥10 treatments (≥3L or ≥4L) over the last year, and switched patients’ treatment from ≥1L to ≥3L. Online surveys were designed to capture patient experience of the general population, resistance and intolerance are challenging to manage.

CONCLUSIONS
• Overall, CML SUN demonstrates the need for a shared treatment decision that balances efficacy and tolerability given among patients and physicians in hematological studies. Treatment options that are both effective and tolerable are needed to help patients stay on therapy longer and avoid treatment switching and the increased risk for on TON, and cost of treatment. While most patients and physicians are satisfied with the efficacy of current TKI treatments, there were differences in perceptions of impacts on their QOL, including mental health, social life, work life, school life, and physical activity.

Patient perceptions of CML treatment effects on everyday life

Patient Perceptions of How CML Treatment Affects Their Life (n=361)

A significant percentage of physicians who interviewed are in the active decision-makers in treatment decision-making, despite reporting to support the treatment of the patient, suggesting lack of reaching patient empowerment and shared decision-making as part of routine clinical practice. This may be because there’s a great difference in terms of treatment selection and goals that can be managed between the patient and physician.

Patient satisfaction with their current TKI treatment

Patient Satisfaction With Their Current TKI Treatment (n=361)

The doctor described only 1 treatment and I had no other choice

The doctor described multiple treatments, we discussed and decided together

The doctor described multiple treatments, recommended 1 treatment, and I agreed with that recommendation

Someone else recommended a treatment and I asked the doctor about it

I found information about different treatment(s) and I asked the doctor about it

I made the decision with significant input from the patient

I made the decision with little input from the patient

I was a mutual decision between the patient and me

I made the decision with little input from the patient

Patient satisfaction with current treatment

Physician Satisfaction With Current Treatment (n=361)

A significant percentage of physicians who interviewed are in the active decision-makers in treatment decision-making, despite reporting to support the treatment of the patient, suggesting lack of reaching patient empowerment and shared decision-making as part of routine clinical practice. This may be because there’s a great difference in terms of treatment selection and goals that can be managed between the patient and physician.

P668

Chronic Myeloid Leukemia Survey on Unmet Needs (CML SUN): Balancing Tolerability and Efficacy Goals of Patients and Physicians Through Shared Treatment Decision-Making

Fabian Leng, Zoe Patakas-Whiteley, Joanna Clemenčič, Cristina Ruiz, Diptidee Pham, Lisa Machado, Nasir Tahmaseb, Hung-Ho Moon, Andrew Gregg, Cornelia Brezovich, Peter Scherl, Pia Falkvist, Cristina Constantinou, Cola Bouquet, Jorge E. Cortez

1Department of Hematology and Oncology, Ghent University Hospital, Kortrijk, Belgium; 2Gumpoldskirchen, Vienna, Austria; 3Kurhaus Bad Bentheim, Germany; 4Novartis Pharma AG, Basel, Switzerland; 5Astellas, Basel, Switzerland; 6Hemotis, Rio de Janeiro, Brazil; 7Gloria-Cesar Carić, Augusta University, Augusta, GA, USA

ACKNOWLEDGEMENTS:
S_H_M. and J_C. received honoraria and consulting fees from Bristol Myers Squibb and provided consultancy for Novartis.

S_H_M. is employed by IPSOS, a consulting company paid by Novartis.

C. Borowczak received research funding and honoraria from Novartis, Incyte, and Pfizer.

J_H_J. received honoraria from Novartis.

L.E. received honoraria from Novartis.

J.C. received research funding and honoraria from Novartis, Incyte, and Pfizer and provided consultancy for Novartis.

J_H_J. is a consultant and member of the board of directors or an advisory committee for Novartis, Incyte, and Pfizer.

I am constantly stressed and worried if my treatment works

I feel emotionally fatigued

I cannot exercise as much as before

I am completely stressed and worried if my treatment works

Impact on your mental health

Impact of QOL, treatment frequency, and method of administration on TON

Quality of life (QOL) and patient self-management skills are important goals of physicians in hematological studies. Resistance and intolerance are challenging to manage.

Physicians, patients, and other stakeholders in CML care have the opportunity to collaborate and raise their expectations for CML treatments in hematological studies. Resistance and intolerance are challenging to manage. Physicians, patients, and other stakeholders in CML care have the opportunity to collaborate and raise their expectations for CML treatments.